Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Darren Keamy as its chief financial officer (CFO) and company secretary starting today.
Mr Keamy is an experienced finance executive with a career spanning over 25 years in corporate finance, financial strategy, and investor relations within the biopharmaceutical industry.
Before joining Imugene, he served as CFO and company secretary at Clinuvel Pharmaceuticals from 2005 to 2024, where he played a pivotal role in the company’s transformation from a small start-up to a cash-generating, profitable, multinational ASX-listed organisation.
During his tenure at Clinuvel, Mr Keamy was instrumental in capital-raising efforts, securing over $95 million through various funding mechanisms. The company graduated from a market capitalisation of approximately $60 million to a high point of more than $2.1 billion.
Imugene’s managing director and CEO, Leslie Chong, said, “Darren’s outstanding experience in financial management, capital markets, and corporate governance within the life sciences sector makes him a valuable addition to Imugene. His proven ability to drive financial performance and strategic growth will support the company as we continue advancing our immuno-oncology pipeline. We are delighted to have him on board.”